New Therapeutic Targets and the Pathobiology of Depression

New Therapeutic Targets and the Pathobiology of Depression

March 2014 – Vol 16 – No. 1

Editor’s Choice

Ronald S. Duman presents new findings on the role of neurotransmitters, particularly glutamate and acetylcholine, in depression, offering promising possibilities for treatment.
Alexander Dayer discusses the role of the serotonin system and of early-life stress in the etiology of psychiatric disorders, particularly depression.
Yogesh Dwivedi writes about the rapidly emerging role of microRNAs in major depressive disorder, and the implications for treatment.

In this issue

Read full text
Pierre Schulz, David Rubinow

Guest editorial

Redesigning antidepressant drug discovery
Florian Holsboer (Germany)

State of the art

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections
Ronald S. Duman (USA)

Translational research

Serotonin-related pathways and developmental plasticity: relevance for psychiatric disorders
Alexandre Dayer (Switzerland)

Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications
Yogesh Dwivedi (USA)

Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder
Daniel Martins-de-Souza (Brazil)

Clinical research

Functional neuroimaging studies of the effects of psychotherapy
Mario Beauregard (USA)

Deep brain stimulation in the treatment of depression
Sibylle Delaloye; Paul E. Holtzheimer (USA)

Endogenous and exogenous electric fields as modifiers of brain activity: rational design of noninvasive brain stimulation with transcranial alternating current stimulation
Flavio Fröhlich (USA)

Neurofeedback and networks of depression
David E. J. Linden (UK)

Special article

Henri Laborit and the inhibition of action
Edward Kunz, MD